Amira Pharmaceuticals raises $25,000,000

Amira Pharmaceuticals, a privately-held biopharmaceutical company focused on developing new drugs to treat inflammatory disease, today announced that it has raised $25 million in a private equity financing The additional funding will enable the company to advance multiple drug candidates through clinical proof of concept, including AM103 to treat respiratory and cardiovascular conditions